A Prospective Observational Study on Prescribing Patterns of Anti-Hypertensive Drugs in Patients with Hypertension
DOI:
https://doi.org/10.26452/ijcpms.v1i4.238Keywords:
Hypertension, Prescribing Pattern, Blood Pressure, Antihypertensive DrugsAbstract
A prospective observational study was carried out among 180 patients for a period of 6 months at in-patient department of cardiology, Apollo hospital. A total of 180 prescriptions with different co-morbidities were enclosed in the present study who met the inclusion criteria. 63% were male and 37% were female with mean average of 36±23.16. 34.4% of the patients were in the age group of 61-70. The common co-morbidities along with hypertension which were seen in the study are diabetes mellitus (38%), coronary artery disease (31%) and chronic kidney disease (9%). The most commonly prescribed therapy was monotherapy given in 116 patients (64.4%) followed by dual therapy given in 59 patients (32.7%) and triple therapy was given only in 5 patients (2.7%). Among the monotherapy, the various class of drugs prescribed were ARB (34.4%), followed by CCB (32.7%), BB (25.8%), ACE inhibitors (3.45%) and B+A (3.45%). Among the dual therapy, the various class of drug combinations prescribed were ARB+CCB (28.8%), followed by ARB+Di(22%), ACE+CCB (20.3%), CCB+BB(15.2%), ARB+BB(11.8%) and CCB+Di(1.69%). In triple drug therapy the various class of drugs used were ARB+BB+CCB (60%) and ARB+Di+CCB (40%). In the present study, it was found that monotherapy was the most commonly prescribed regimen followed by dual and triple therapy. ARB was the most commonly prescribed class as monotherapy, ARB+CCB as dual therapy and ARB+BB+CCB as triple therapy. In monotherapy, commonly used drug was telmisartan. In dual therapy, commonly used drug combination was telmisartan+amlodipine and in triple therapy, commonly used drug combination was telmisartan+metoprolol+clinidipine.
Downloads
Published
How to Cite
Issue
Section
License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.